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ABSTRACT  
 
Objectives 
This study aims to identify the existence and relation between autoantibody clusters 
and clinical subsets in Chinese SLE patients. 
Methods 
The data of 1928 SLE patients from Hong Kong were analysed. Using cluster analysis, 
patients were grouped by autoantibodies into clusters. The frequencies of different 
clinical manifestations were then compared between each cluster. Separate association 
analyses between individual autoantibodies and clinical manifestations, as well as 
between clinical manifestations were also performed without any prior clustering. 
Results 
Three separate autoantibody clusters were identified each with significantly different 
clinical manifestations. Cluster 1 was characterized by anti-dsDNA and the greatest 
prevalence of renal disorder but the lowest frequencies of other clinical manifestations. 
Cluster 2 was represented by the predominance of anti-Sm, anti-RNP and aPL, with 
greater prevalence of malar rash, oral ulcers, arthritis and serositis. Cluster 3 was 
characterized by anti-Ro and anti-La with greater prevalence of discoid rash, 
photosensitivity and haematological involvement. Individual association analysis also 
revealed similar findings. Patients of Cluster 2 and Cluster 3 were more closely 
related, whilst Cluster 1 was more distinct, associated with renal disorder only and 
negatively or not associated with other manifestations. 
Conclusions 
We conclude that autoantibody clustering and clinical subsets exist in SLE patients of 
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our locality. These clusters may be viewed as a bipolar spectrum of related 
autoantibody and clinical manifestations. On one end are patients with over-
representation of anti-dsDNA and renal disorder; whilst on the other end are two 
distinct autoantibody clusters (anti-Sm/anti-RNP/aPL and anti-Ro/anti-La) with 
overlapping of other clinical manifestations. 
Key words:   
Lupus Erythematosus, Systemic 
Autoantibodies 
Cluster Analysis 
Multivariate Analysis 
Prevalence 
Epidemiology 
Chinese 
Hong Kong 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with 
heterogeneous manifestations. The diagnosis of SLE is usually made when patients 
has developed four or more out of the eleven American College of Rheumatology 
(ACR) criteria [1], which can range from different organ manifestations to production 
of various autoantibodies. Individual autoantibodies can be used to reflect or predict 
disease activity, and some are associated with specific disease manifestations [2, 3].  
Subsets of patients with distinct patterns of disease manifestations [4-6] and the 
clustering of autoantibodies [3, 7] have been previously reported, but seldom have 
these two phenomena been analyzed together. Identification of patient clusters by 
autoantibody profile, in addition to each cluster’s associated features, may potentially 
be useful for disease prediction. For example, if tested positive for a certain 
autoantibody, a patient would likely belong to a certain cluster and thus more prone to 
develop other specific laboratory or clinical manifestations. 
Cluster analysis is a statistical method which partitions cases by grouping them into 
clusters based on similarities between variables; in this study, different autoantibody 
production. However, cluster analysis does not provide an explanation as why these 
clusters exist, and techniques for determining the reliability and validity of clusters 
have not yet been developed. Therefore separate association analysis between 
individual autoantibodies and clinical manifestations can also be performed.  
In this study, we utilize cluster analysis to identify the existence of autoantibody 
clustering with specific subsets of clinical manifestations in Chinese SLE patients. 
The predominant autoantibodies of each cluster were also individually associated with 
the over-represented clinical manifestations of the same cluster. Furthermore, there 
were significant associations between the representative manifestations of the same 
5 
 
and certain different clusters, which reiterated the observations in cluster analysis. 
Our findings therefore suggest that autoantibody clustering and the grouping of 
clinical manifestations may be inter-related.  
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MATERIAL AND METHODS 
Patient population 
All patients were of Chinese ethnicity and diagnosed with SLE, having fulfilled at 
least four of the 1997 Revised Criteria for the Classification of SLE [1]. The patients 
were recruited from 5 regional hospitals throughout Hong Kong (Queen Mary 
Hospital, Queen Elizabeth Hospital, Princess Margaret Hospital, Tuen Mun Hospital 
and Pamela Youde Nethersole Eastern Hospital) as part of a multi-centre study 
approved by the Institutional Review Board of the University of Hong Kong and 
Hospital Authority Hong Kong West Cluster; Research Ethics Committee, Kowloon 
Central and Kowloon East; Clinical Research Ethics Committee, Kowloon West 
Cluster; New Territories West Cluster, Clinical and Research Ethics Committee; and 
Ethics Committee, Hong Kong Easter Cluster. All patients gave informed consent. 
Clinical data were collected by medical record review between 2007 and 2009 and 
inputted into a clinical database. 
 
Data collection 
This was a cross-sectional retrospective study with all clinical data drawn from the 
study’s database Recorded data from this database included gender, age of onset, 
clinical manifestations and presence of autoantibodies. Clinical manifestations (malar 
rash, discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal disorder, 
neurological involvement, haematological involvement) and autoantibody (anti-
double stranded DNA (dsDNA), anti-Smith (anti-Sm) and anti-phospholipid 
antibodies (aPL)) were defined according to the revised ACR classification criteria for 
SLE [1]. Additional autoantibodies associated with SLE were also studied, including: 
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anti-Ro, anti-La and anti-ribonucleoprotein (anti-RNP). Patients were considered 
positive for certain disease manifestations as diagnosed by physicians in respective 
hospitals, and considered positive for autoantibodies if there were any positive results 
in previous serological tests performed at respective hospitals.  
Statistical methods 
Cluster analysis was performed using the K-means algorithm to group patients with 
similar autoantibody profiles together. However, K-means clustering is intended for 
clustering quantitative variables and the presence of autoantibody production is 
categorical. Factor analysis was therefore performed first with the factor loading 
scores used in the K-means algorithm. Further details on factor and cluster analyses 
can be found in the supplementary data and tables. 
The frequencies of different autoantibodies and clinical manifestations between 
cluster groups were compared using the chi-square test with Yates' correction for 
overall p-values and the Fisher’s exact test to compare between individual clusters. To 
compensate for the effect of multiple comparisons in the Fisher’s exact tests, 
Bonferroni correction was used and only p-values <0.001 were considered significant. 
Further association analyses using the chi-square test with Yates' correction were 
performed and odds ratios (OR) with 95% confidence intervals (CI) were used to 
quantify the relationship between individual autoantibodies and clinical 
manifestations, as well as between individual clinical manifestations. The Fisher’s 
exact tests were used to calculate the p-values and, after Bonferroni correction, only 
p-values <0.001 were considered significant. SAS version 9.1 was used for 
calculating the Akaike's information criterion (AIC) and Bayesian information (BIC) 
criterion. SPSS version 11.5 was used for all other analyses. 
8 
 
 
RESULTS 
A total of 1928 Chinese SLE patients from Hong Kong were studied. There were 
1771 females and 157 males, making a female:male ratio of 11.3:1. The mean (SD) 
age of onset was 29.8 (13) years, and the mean (SD) disease duration for all patients 
was 13.1 (8.6) years.  
Data regarding arthritis, serositis and neurological involvement were missing for 256 
patients, thus any analyses involving these manifestations were calculated after 
exclusion of these patients. However since clustering was by autoantibody production 
only, and not clinical manifestations, this would not have any effect on clustering. All 
other data was otherwise available for 1928 patients. Baseline characteristics 
including prevalence of clinical manifestations and autoantibody profile in 
comparison to previous cohorts of other ethnicities are shown in Table 1. 
 
Autoantibody clusters and their differences in clinical manifestations 
Using cluster analysis, the 1928 patients were grouped into three separate clusters of 
autoantibodies, and each cluster had significantly different subsets of clinical 
manifestations. The frequencies of individual autoantibodies and clinical 
manifestations in each respective cluster are shown in Table 2.  
Cluster 1 consisted of 1211 patients represented by a higher frequency of anti-dsDNA, 
which was marginally insignificant when compared to Cluster 2 but significantly 
different to Cluster 3 (78.1% vs. 72.6% [Cluster 2, p=0.0194], 43.9% [Cluster 3, 
p<0.0001]). These patients also had significantly lower prevalence of all other 
autoantibodies; namely aPL (33.4% vs. 50.6% [Cluster 2, p<0.0001], 46.3% [Cluster 
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3, p<0.0001]), anti-Sm (0% vs. 45.4% [Cluster 2, p<0.0001], 2.7% [Cluster 3, 
p<0.0001]), anti-Ro (29.5% vs. 58.4% [Cluster 2, p<0.0001], 89.5% [Cluster 3, 
p<0.0001]), anti-La (0% vs. 5.7% [Cluster 2, p<0.0001], 67.0% [Cluster 3, p<0.0001]) 
and anti-RNP (0% vs. 84.2% [Cluster 2, p<0.0001], 7.5% [Cluster 3, p<0.0001]). 
Similarly for clinical manifestations, there was significantly greater prevalence of 
renal disorder (60.3% vs. 48.9% [Cluster 2, p<0.0001], 44.6% [Cluster 3, p<0.0001]), 
but lowest prevalence of almost all other clinical manifestations. The only exceptions 
were haematological involvement (53.6% vs. 61.2% [Cluster 2, p=0.0075]), serositis 
(12.7% vs. 19.4% [Cluster 2, p=0.0028], 10.6% [Cluster 3, p=0.3967]) and 
neurological involvement (7.9% vs. 7.7% [Cluster 2], 8.3% [Cluster 3], overall 
p=0.968), which were not significantly different when compared to one or either 
clusters. 
Four-hundred-and-twenty-three patients were assigned to Cluster 2 This cluster had 
significantly greater prevalence of anti-Sm (45.4% vs. 0% [Cluster 1, p<0.0001], 
2.7% [Cluster 3, p<0.0001]) and anti-RNP (84.2% vs. 0% [Cluster 1, p<0.0001], 7.5% 
[Cluster 3, p<0.0001]) when compared to bother clusters, and greater prevalence of 
aPL when compared to Cluster 1 (50.6% vs. 33.4%, p<0.0001). Cluster 2 had the 
highest prevalence of malar rash (67.1% vs. 47.0% [Cluster 1, p<0.0001]) and 
arthritis (72.0% vs. 53.5% [Cluster 1, p<0.0001]) but these clinical manifestations 
were only significantly different when compared with Cluster 1, but not with Cluster 
3 (all p-values >0.001). Oral ulcers (23.4% vs. 7.9% [Cluster 1, p=0.0122], 21.1% 
[Cluster 3, p=0.5243]) and serositis (19.4% vs. 12.7% [Cluster 1, p=0.0028], 10.6% 
[Cluster 3, p=0.0032]) were also most prevalent in this group, but both did not reach 
statistical significance when compared with other clusters individually. 
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The remaining 294 patients were assigned to Cluster 3, which was characterized by 
the significant over-representation of anti-Ro (89.5% vs. 29.5% [Cluster 1, p<0.0001], 
58.4% [Cluster 2, p<0.0001]) and anti-La (67.0% vs. 0% [Cluster 1, p<0.0001], 5.7% 
[Cluster 2, p<0.0001).  The frequencies of photosensitivity (32.7% vs. 20.3% [Cluster 
1, p<0.0001], arthritis (68.1% vs. 53.5% [Cluster 1, p<0.0001] and haematological 
disorder (62.9% vs. 53.6% [Cluster 1, p=0.004] were all significantly greater than 
Cluster 1 but not significantly different with Cluster 2 (all p-values >0.001). Discoid 
rash was also most prevalent in this group (11.9% vs. 7.9% [Cluster 1, p=0.0373], 
10.9% [Cluster 2, p=0.071]), but did not reach statistical significance when compared 
with other clusters individually. 
 
Associations between individual autoantibodies and clinical manifestations 
Separate association analysis between individual autoantibodies and clinical 
manifestations echoed the previous observations from cluster analysis. Predominant 
autoantibodies showed associations with the over-represented clinical manifestations 
of the same cluster. The OR and CI are shown in Table 3. For both Table 3 and Table 
4, the data has been presented so that the representative autoantibodies/clinical 
manifestations of each cluster (as identified by cluster analysis) are listed together for 
easier visualisation; no prior clustering was performed for this analysis. No 
associations between any autoantibodies and neurological involvement were found 
(data not shown). 
Anti-dsDNA was positively associated with renal disorder (OR=2.37, CI=1.93-2.90) 
and negatively associated with photosensitivity (OR=0.68, CI=0.54-0.84). 
Furthermore, renal disorder was not associated with all other autoantibodies from 
other clusters. This is consistent with the observations of Cluster 1 from previous 
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cluster analysis. Serositis (OR=2.04, CI=1.42-2.92) and haematological involvement 
(OR=1.56, CI=1.28-1.91) were exceptions and found to be positively associated with 
anti-dsDNA. 
Anti-Sm, anti-RNP and aPL (predominant autoantibodies of Cluster 2) were 
individually associated with malar rash, arthritis and serositis (which were all 
representative clinical manifestations of the same cluster during cluster analysis), 
despite some associations failing to reach statistical significance after Bonferroni 
correction. These three autoantibodies also did not have associations with oral ulcers. 
Furthermore, aPL was associated with photosensitivity (OR=1.47, CI=1.19-1.81) and 
haematological involvement (OR=1.43, CI=1.19-1.72); and anti-RNP with 
photosensitivity (OR=1.52, CI=1.19-1.95), which were all over-represented clinical 
manifestations of Cluster 3.  
Likewise, anti-Ro, and anti-La (characteristic autoantibodies of Cluster 3) were also 
associated with all the representative clinical manifestations of the same cluster, 
namely: discoid rash, photosensitivity and haematological involvement (although the 
associations of anti-La with discoid rash and photosensitivity were not significant). 
Anti-Ro and anti-La also showed significant associations with the predominant 
clinical manifestations from Cluster 2. Anti-Ro was significantly associated with 
malar rash (OR=1.74, CI=1.45-2.09) and arthritis (OR=1.96, CI=1.61-2.40). 
 
Associations between individual clinical manifestations 
Individual association analysis was performed between different clinical 
manifestations. The OR and CI for all associations are shown in Table 4. In most 
cases the associations were concordant with previous patterns. Renal disorder (Cluster 
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1) was negatively associated with all other manifestations, except with serositis 
(OR=1.56, CI=1.17-2.08) and haematological involvement (OR=1.01, CI=0.84-1.21). 
However there were again much intra- and inter-cluster associations with the over-
represented clinical manifestations of Cluster 2 and Cluster 3 as identified by cluster 
analysis. Eight out of the twelve inter-cluster associations between the over-
representative clinical manifestations reached statistical significance. Associations 
with serositis was again an exception (vs. discoid rash [OR=0.93, CI=0.57-1.53] and 
photosensitivity [OR=0.73, CI=0.51-1.03]). The associations of  discoid rash with 
arthritis (OR=1.06, CI=0.75-1.49) and oral ulcers (OR=1.72, CI=1.21-2.44) were also 
not significant. Neurological involvement, not previously significantly different 
between clusters or associated with individual autoantibodies, was individually 
associated with serositis (OR=2.82, CI=1.88-4.23) and haematological involvement 
(OR=2.05, CI=1.38-3.04) (data not shown). 
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DISCUSSION 
This is one of the largest observational studies of autoantibody and clinical 
manifestations of SLE patients reported. Although cluster analysis based on clinical 
patterns have been previously performed [6], we are first to report of autoantibody 
clustering in our locality and have employed a different statistical approach. In order 
to avoid inappropriately clustering binary data [8], we first performed factor analysis 
and used the factor loading scores in the K-means algorithm. Furthermore, we also 
performed separate association analysis to identify the relationships between 
individual variables. Clinicians may be especially interested in these associations 
between individual autoantibodies and various disease manifestations; as well as 
associations among individual clinical features only, without reference to 
autoantibody profile. It is also much easier to interpret and explain these individual 
associations within the context of known pathophysiology and biological processes in 
comparison to the agglomerated data of cluster analysis. 
 The demographics of the patients in this study (Table 1) were mostly comparable to 
previous large Mainland Chinese [9], Caucasian [10] and African-Black [11] cohorts. 
Our study and that by Feng et al. [9] both show a higher prevalence of anti-Ro (45.0% 
and 34.3% vs. 25%) and renal involvement (55.4% and 55.9% vs. 39%) in Chinese 
patients when compared to Caucasians [10]. This is consistent with previous reports 
[12, 13] and it has been suggested that the presence of anti-Ro may contribute to the 
likelihood of developing renal involvement [14]. However this pattern is not 
consistent when Chinese patients are compared to African Blacks [11]. African 
Blacks had a higher frequency of anti-Ro (60.5%) despite a lower prevalence of renal 
disorder (48.6%). This is an important observation as renal disease is a major cause of 
morbidity in our SLE patients [15] and further research into the relationship between 
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anti-Ro and renal involvement in Chinese patients would be of great value. 
Furthermore, such population differences of autoantibodies and clinical 
manifestations amongst different ethnicities may lead to different clustering or 
association results. An example of this can be seen if we compare our results to other 
studies such as that by To et al. [3] which studied autoantibody clustering amongst 
patients of different ethnicities. Although we observe the same clustering of anti-Sm 
and anti-RNP, we did not identify their reported clustering of anti-dsDNA with anti-
Ro/anti-La or with the aPL. This may be due to a comparatively higher prevalence of 
anti-dsDNA in patients of our locality in comparison to their mixed patient sample 
(71.6% vs. 58.2%). 
In this study we identify three separate clusters of patients by autoantibody profile, 
each showing distinct patterns of clinical manifestations (Table 2). Despite supporting 
evidence from Euclidean distances between cluster centroids, as well as the AIC and 
BIC criteria, determining the optimum number of clusters remains difficult. However, 
the presence of these three clusters is consistent with prior reports of various SLE 
subsets and relates well with known biological processes. The details of each 
autoantibody cluster and associations with various clinical manifestations are 
elaborated on as follows.  
Cluster 1 consisted of 62.8% of all patients, with the highest prevalence of anti-
dsDNA and renal disorder. Patients from this cluster also had significantly lower 
prevalence of all other autoantibodies and no patients were positive for anti-Sm, anti-
La or anti-RNP.  Individual association analysis (Table 3) further showed anti-dsDNA 
to be strongly associated with renal disorder, but generally not with other 
manifestations. A very consistent pattern can also be observed in the association 
analysis between different clinical manifestations (Table 4) with renal disorder 
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negatively associated with almost all other manifestations. Interestingly, serositis was 
repeatedly an exception to these patterns, and individual association analysis of 
haematological involvement showed positive findings with anti-dsDNA and 
insignificant results with renal disorder. Although relationships between 
haematological involvement with renal disorder [3, 10, 16] and anti-dsDNA [17] have 
been reported by some, the associations with serositis have not been well documented. 
Anti-Sm, anti-RNP and aPL were over-represented by patients of Cluster 2 which 
consisted of 21.9% of all patients; and anti-Ro and anti-La were predominant in 
Cluster 3, which consisted of 15.2% of all patients (Table 2). The clustering of anti-
Sm with anti-RNP [18, 19] and anti-Ro with anti-La [10, 19] have been reported 
previously. The coexistence of anti-Sm and anti-RNP has been attributed to the 
similarity and cross-reactivity between the targets of these two antibodies [20]; whist 
anti-Ro and anti-La are both induced by common small cytoplasmic 
ribonucleoproteins [21, 22]. On the contrary, the associations of aPL with other 
autoantibodies have not been well described. However, there was no significant 
difference in aPL between Cluster 2 and Cluster 3 (50.6% [Cluster 2] vs. 46.3% 
[Cluster 3, p=0.259]), and only differentiating value is its relative infrequency in 
Cluster 1 (33.4%, both p <0.0001). 
Cluster 2 (anti-Sm/anti-RNP/aPL) had the highest prevalence of malar rash, oral 
ulcers, arthritis and serositis, and Cluster 3 (anti-Ro/anti-La) had the highest 
prevalence of discoid rash, photosensitivity and haematological involvement (Table 2). 
Although many associations remain controversial, these results were consistent with 
many previous reports. For example, in Cluster 2: the association between anti-RNP 
and arthritis [23]; between anti-Sm and serositis [24]; and in Cluster 3: between anti-
Ro and photosensitivity [25], discoid lupus and haematological involvement [26]. 
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There were many associations observed between Cluster 2 and Cluster 3, both 
between their over-represented clinical manifestations and autoantibodies (Table 3), 
as well as between their clinical manifestations (Table 4). There were also 
consistently negative associations between these autoantibodies with renal disorder. In 
contrast, anti-dsDNA, the predominant autoantibody of Cluster 1, was strongly 
associated with renal disorder but seldom with the predominant features of other 
clusters. These observations make sense on both the autoantibody and clinical 
manifestation levels. On the autoantibody level, the pathogenic role for anti-dsDNA 
in renal involvement has been well established [27, 28]; whilst anti-Sm [29, 30], anti-
RNP [31-33], and the combination of anti-Ro/anti-La [34] have been described to 
have little or even protective roles in the development of renal disease. In fact, anti-
RNP was originally described in patients with mixed connective tissue disease who 
lacked renal involvement and to occur only rarely with anti-dsDNA [35, 36]. Whilst 
on the level of clinical manifestations, observations by physicians have long 
suggested that subsets of lupus patients exist. A consistent observation is that patients 
with renal disease seem to be at decreased risk of developing other manifestations [4]. 
Of particular interest, this described subset of patients has shown to have greater 
prevalence of haematological involvement [6, 16]. This is again compatible with our 
results, where haematological involvement was an exception to the consistently 
negative associations observed with anti-dsDNA and renal disorder (Table 3 and 
Table 4).  
The prevalence of neurological involvement was not significantly different between 
clusters, and no association with other clinical manifestations were identified. This 
may be explained by the low prevalence of neurological involvement in patients of 
our locality (7.9%) compared with other ethnicities (e.g. African Blacks: 17.1%), 
which is consistent with previous reports [37, 38]. 
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In interpretation of the results of cluster and association analysis as a whole, this study 
proposes that the clustering of autoantibody and subsets of clinical manifestations 
may be related. Although further studies are required to explore any potential 
underlying mechanisms, from these observations we hypothesize that the clustering of 
autoantibodies may partially account for the observed clinical subsets. Various 
clusters of autoantibodies may play common or complementary roles in the 
pathogenesis of single or similar clinical manifestations. An example of this can be 
seen between anti-Ro and anti-La with photosensitivity (Cluster 3). Both in vitro and 
in vivo experiments have demonstrated that ultraviolet radiation helps the binding of 
anti-Ro and anti-La onto the surface of keratinocytes [39], and it has been suggested 
that the binding of these two autoantibodies may have common pathogenic roles in 
this photosensitive inflammatory skin manifestation [40, 41]. 
Overall, in this study we observe that patients can be clearly separated into three 
clusters based in autoantibody profile. Although Cluster 2 and Cluster 3 clearly 
cluster very distinctly by autoantibody production, there is much overlapping of their 
representative clinical manifestations. These findings also suggest that SLE may be 
viewed as a disease with a bipolar spectrum of autoantibody and clinical 
manifestations; with these three clusters of patients viewed on two different ends of 
disease manifestations. On one end are patients from Cluster 1 (anti-dsDNA), with the 
most renal disorder but lowest prevalence of other manifestations. On the other end 
are patients of Cluster 2 (anti-Sm/anti-RNP/aPL) and Cluster 3 (anti-Ro/anti-La). The 
exceptions of haematological involvement and serositis may suggest that these 
manifestations overlap between these two extremes. Furthermore, neurological 
involvement may exist independently without any significant between clusters or 
particular autoantibody associations. 
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There are numerous limitations to this study. For example, patients in this study were 
recruited from regional hospitals and may lead to an over-representation of patients 
with more severe manifestations. This may explain the larger number of patients in 
Cluster 1 (n=1211) than in Cluster 2 (n=423) or Cluster 3 (n=294). Secondly, other 
than anti-Ro, anti-La and anti-RNP, data for other manifestations not included in the 
ACR criteria [1] or more detailed sub-classifications were unavailable. However, 
given the pervasive adoption of these criteria and being able to compare with other 
research, we believe the choice of studied variables were appropriate. Furthermore, as 
this is only an observational study, we also plan to use a predictive approach on an 
independent sample in future study in order to validate our clustering results. 
In conclusion, these findings may help guide the future study of potential common 
pathogenic mechanisms within autoantibody clusters and their effect on disease 
manifestations. It would be interesting to explore if these relationships between 
clinical subsets and autoantibody clusters may extend to the genetic level, for example 
by using these clusters in subphenotype analysis in genetic association studies. 
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KEY MESSAGES 
 
 
1. Three autoantibody clusters with different subsets of clinical manifestations 
exist in Chinese SLE patients. 
2. SLE can be viewed as a bipolar spectrum of autoantibody and clinical 
manifestations. 
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 Table 1 – Prevalence of autoantibodies and clinical manifestations in Hong Kong 
Chinese patients compared to previous cohorts. 
 Present study 
(Hong Kong) 
Mainland 
Chinese [8] 
Caucasian [9] African Blacks 
[10]  
Number of patients 1928 1790 1000 111 
Female (%) 91.9 90.2 91 92.5 
Mean (SD) age of onset 29.8 (13) 31.0 (12) 29 (13) 35.1 
     
Autoantibodies (%)         
Anti-dsDNA 71.6 41.8 78 66.7 
aPL 39.2 - - - 
Anti-Sm 10.4 27.6 10 44.2 
Anti-Ro 45.0 34.3 25 60.5 
Anti-La 11.5 14.9 19 28.4 
Anti-RNP 19.6 16.2 13 65.5 
     
Clinical manifestations (%)         
Malar rash 53.1 50.2 58 55.0 
Discoid rash 9.2 5.8 10 28.8 
Photosensitivity  24.6 14.9 45 33.3 
Oral ulcer 19.5 13.6 24 21.6 
Arthritis# 59.6 63.9 84 62.2 
Serositis# 13.8 16.6 36 28.2 
Renal disorder 55.4 55.9 39 48.6 
Neurological involvement# 7.9 8.9 - 17.1 
Haematological  involvement 56.5 - - 60.5 
 
# Clinical manifestations where data were available for 1672 patients.
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Table 2 – Clustering of 1928 SLE patients into three clusters by cluster analysis based on autoantibody profile. 
 
  Cluster 1 Cluster 2 Cluster 3 
Overall p-value 
p-value between individual clusters 
 a) (n = 1211) (n = 423) (n = 294) 1 vs. 2 1 vs. 3 2 vs. 3 
Female 1007 (91.4%) 391 (92.4%) 273 (92.9%) 0.637 . . . 
Mean (SD) age of onset 29.2 (13.2) 30.0 (12.0) 31.9 (13.5) 0.008* 0.75 0.006* 0.156 
        
Anti-dsDNA 946 (78.1%) 306 (72.6%) 129 (43.9%)‡ <0.0001* 0.0194 <0.0001* <0.0001* 
aPL 405 (33.4%)‡ 214 (50.6%) 136 (46.3%) <0.0001* <0.0001* <0.0001* 0.259 
Anti-Sm 0 (0%)‡ 192 (45.4%)‡ 8 (2.7%)‡ <0.0001* <0.0001* <0.0001* <0.0001* 
Anti-Ro 357 (29.5%)‡ 247 (58.4%)‡ 263 (89.5%)‡ <0.0001* <0.0001* <0.0001* <0.0001* 
Anti-La 0 (0%)‡ 24 (5.7%)‡ 197 (67.0%)‡ <0.0001* <0.0001* <0.0001* <0.0001* 
Anti-RNP 0 (0%)‡ 356 (84.2%)‡ 22 (7.5%)‡ <0.0001* <0.0001* <0.0001* <0.0001* 
 
b) Cluster 1 Cluster 2 Cluster 3 Overall p-value 1 vs. 2 1 vs. 3 2 vs. 3 
Malar rash 569 (47.0%)‡ 284 (67.1%) 171 (58.2%) <0.0001* <0.0001* 0.0007* 0.0147 
Discoid rash 96 (7.9%) 46 (10.9%) 35 (11.9%) 0.042* 0.7193 0.0373 0.071 
Photosensitivity  246 (20.3%)‡ 132 (31.2%) 96 (32.7%) <0.0001* <0.0001* <0.0001* 0.6844 
Oral ulcer 215 (17.8%) 99 (23.4%) 62 (21.1%) 0.031* 0.0122 0.208 0.5243 
Arthritis# 571 (53.5%)‡ 252 (72.0%) 173 (68.1%) <0.0001* <0.0001* <0.0001* 0.3213 
Serositis# 136 (12.7%) 68 (19.4%) 27 (10.6%) 0.002* 0.0028 0.3967 0.0032 
Renal disorder 730 (60.3%)‡ 207 (48.9%) 131 (44.6%) <0.0001* <0.0001* <0.0001* 0.2548 
Neurological involvement# 84 (7.9%) 350 (7.7%) 21 (8.3%) 0.968 . . . 
Haematological involvement 649 (53.6%) 259 (61.2%) 185 (62.9%) 0.002* 0.0075 0.004* 0.6959 
(a) Comparison of the frequencies of different autoantibodies between each cluster. 
(b) Comparison of the frequencies of different clinical manifestations between each cluster. 
Results are displayed as the absolute number of patients (proportion of cluster) for given autoantibody or clinical manifestation. 
‡ denotes values are significantly different from the other two clusters 
* denotes associations reaching statistical significance (p<0.05 for overall p-value, and p<0.001 for between clusters after Bonferroni correction) 
# denotes clinical manifestations where data were available for 1672 patients. 
Bold text denotes clusters with the greatest prevalence. 
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Table 3 – Associations between individual autoantibodies and clinical manifestations. 
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Renal disorder1 
2.37* 
(1.93 - 2.90) 
p<0.0001 
0.79 
(0.59 - 1.05) 
p=0.115 
0.76 
(0.61 - 0.96) 
p=0.021 
0.81 
(0.67 - 0.97) 
p=0.024 
0.75 
(0.63 - 0.90) 
p=0.002 
0.66 
(0.50 - 0.87) 
p=0.004 
Malar rash2 
1.05 
(0.86 - 1.28) 
p=0.649 
1.65* 
(1.22 - 2.24) 
p=0.001 
1.80* 
(1.42 - 2.27) 
p<0.0001 
1.29 
(1.07 - 1.55) 
p=0.007 
1.74* 
(1.45 - 2.09) 
p<0.0001 
1.20 
(0.90 - 1.59) 
p=0.224 
Arthritis2 
1.21 
(0.97 - 1.50) 
p=0.086 
1.57 
(1.11 – 2.21) 
p=0.01 
2.16* 
(1.64 - 2.83) 
p<0.0001 
2.01* 
(1.62 – 2.49) 
p<0.0001 
1.96* 
(1.61 – 2.40) 
p<0.0001 
1.61 
(1.17 – 2.24) 
p=0.004 
Serositis2 
2.04* 
(1.42 - 2.92) 
p<0.0001 
1.63 
(1.08 - 2.45) 
p=0.024 
1.69 
(1.22 – 2.33) 
p=0.002 
1.16 
(0.87 - 1.55) 
p=0.332 
1.27 
(0.96 - 1.68) 
p=0.101 
1.10 
(0.72 - 1.68) 
p=0.655 
Oral ulcers2 
0.80 
(0.53 - 1.02) 
p=0.074 
1.35 
(0.95 - 1.91) 
p=0.091 
1.21 
(0.92 - 1.59) 
p=0.192 
0.98 
(0.78 - 1.24) 
p=0.906 
1.34 
(1.07 - 1.68) 
p=0.013 
1.06 
(0.75 - 1.51) 
p=0.719 
Discoid rash3 
0.82 
(0.59 - 1.14) 
p=0.255 
1.90 
(1.24 - 2.90) 
p=0.004 
1.14 
(0.78 - 1.66) 
p=0.489 
1.57 
(1.15 - 2.14) 
p=0.005 
1.75* 
(1.28 - 2.40) 
p=0.0005 
1.45 
(0.93 - 2.23) 
p=0.107 
Photosensitivity3 
0.68* 
(0.54 - 0.84) 
p=0.001 
1.25 
(0.90 - 1.74) 
p=0.193 
1.52* 
(1.19 - 1.95) 
p=0.001 
1.47* 
(1.19 - 1.81) 
p=0.0003 
1.51* 
(1.23 - 1.86) 
p=0.0001 
1.46 
(1.08 - 1.98) 
p=0.02 
Haematological  
involvement3 
1.56* 
(1.28 - 1.91) 
p<0.0001 
1.31 
(0.97 - 1.77) 
p=0.083 
1.40 
(1.11 - 1.77) 
p=0.005 
1.43* 
(1.19 - 1.72) 
p=0.0002 
1.54* 
(1.29 - 1.85) 
p<0.0001 
1.64* 
(1.22 - 2.20) 
p=0.001 
 
Results are displayed as the odds ratio (95% confidence interval) and p-value for each 
association. 
* denotes associations reaching statistical significance (p<0.001) 
1,2,3 denotes over-represented autoantibodies or clinical manifestations of Cluster 1, 
Cluster 2 or Cluster 3 from cluster analysis (Table 2) 
Bold text denotes associations between the over-represented clinical manifestations of 
the same cluster from cluster analysis (Table 2) 
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Table 4 – Associations between individual clinical manifestations. 
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Renal disorder1 
0.71* 
(0.59 - 0.85) 
p=0.0002 
0.57* 
(0.46 - 0.69) 
p<0.0001 
1.56 
(1.17 - 2.08) 
p=0.003 
0.70 
(0.56 - 0.87) 
p=0.002 
0.57* 
(0.42 – 0.79) 
p=0.001 
0.41* 
(0.33 - 0.51) 
p<0.0001 
1.01 
(0.84 - 1.21) 
p=0.963 
Malar rash2 . 
3.04* 
(2.48 - 3.73) 
p<0.0001 
0.84 
(0.64 - 1.11) 
p=0.227 
2.78* 
(2.17 - 3.56) 
p<0.0001 
1.81* 
(1.32 – 2.51) 
p=0.0003 
5.71* 
(4.42 - 7.36) 
p<0.0001 
1.36* 
(1.14 - 1.63) 
p=0.001 
Arthritis2  . . 
1.30 
(0.98 - 1.74) 
p=0.083 
2.53* 
(1.93 - 3.32) 
p<0.0001 
1.06 
(0.75 – 1.49) 
p=0.796 
2.29* 
(1.79 - 2.94) 
p<0.0001 
1.47* 
(1.21 - 1.79) 
p=0.0002 
Serositis2  . .  . 
1.10 
(0.78 - 1.54) 
p=0.598 
0.93 
(0.57 – 1.53) 
p=0.902 
0.73 
(0.51 - 1.03) 
p=0.08 
1.77* 
(1.31 - 2.39) 
p=0.0001 
Oral ulcer2  . . .  . 
1.72 
(1.21 – 2.44) 
p=0.004 
2.00* 
(1.57 - 2.56) 
p<0.0001 
1.96* 
(1.54 - 2.50) 
p<0.0001 
Discoid rash3  . .  . . . 
2.99* 
(2.18 – 4.11) 
p<0.0001 
1.07 
(0.78 – 1.46) 
p=0.691 
Photosensitivity3  . .  . . . . 
1.06 
(0.86 - 1.31) 
p=0.594 
 
Results are displayed as the odds ratio (95% confidence interval) and p-value for each 
association. 
* denotes associations reaching statistical significance (p<0.001) 
1,2,3 denotes over-represented autoantibodies or clinical manifestations of Cluster 1, 
Cluster 2 or Cluster 3 from cluster analysis (Table 2) 
Bold text denotes associations between the over-represented clinical manifestations of 
the same cluster from cluster analysis (Table 2) 
 
 
